Electromed, Inc.
Close on Oct 19, 2026
- Market cap
- $239.32M
- P/E (TTM)
- 21.1
- Dividend yield
- –
About Electromed
Electromedical & Electrotherapeutic Apparatus, SIC 3845
Electromed, Inc. develops, manufactures, markets, and sells medical devices that provide airway clearance therapy. Its core product offering is the SmartVest Airway Clearance System, available in models such as SmartVest SQL and SmartVest Clearway, along with Single Patient Use garments and wraps. These devices use high-frequency chest wall oscillation to clear retained mucus from the lungs. Electromed primarily serves individuals suffering from compromised pulmonary function associated with conditions like bronchiectasis, cystic fibrosis, and neuromuscular diseases. Its customer base includes homecare patients as well as inpatient populations within hospital intensive care and post-surgical units.
The company markets its products primarily in the United States across home health care and acute care hospital channels, and it maintains authorization for device distribution in select international countries. Electromed conducts its corporate operations from its principal executive offices located in New Prague, Minnesota.
Summary of the business section of Electromed's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Electromed, Inc.
- Founded
- 1992
- Headquarters
- New Prague, MN
- Address
- 500 Sixth Avenue Nw 56071
- Phone
- (952) 758-9299
- Employees
- 197, Jun 30, 2026
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- Minnesota
- Fiscal year ends
- June 30
- Auditor
- RSM US LLP, Minneapolis, Minnesota
Stock & identifiers
- Ticker
- ELMD
- Exchange
- NYSE
- IPO date
- Aug 13, 2010
- Shares outstanding
- 8M, Aug 19, 2026
- Public float
- $223.72M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1488917
- CUSIP
- 285409108
- ISIN
- US2854091087
- EIN
- 41-1732920
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| James L. Cunniff | CEO and President, Director | 145,080 |
| Bradley M. Nagel | Chief Financial Officer | 22,762 |
| Kathleen Skarvan | Director | 39,184 |
| Andrew Summers | Director | 282,367 |
| Stan K. Erickson | Director | 40,317 |
| Gregory Fluet | Director | 21,000 |
| Andrea M. Walsh | Director | 18,000 |
| Kathleen A. Tune | Director | 15,000 |
| Joseph L. Galatowitsch | Director | 15,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 James L. Cunniff | $1.81M | $4.27M | $836.16K | $395 | – |
| FY2025 James L. Cunniff | $1.49M | $4.85M | $756.67K | $205 | – |
| FY2025 PEO1 | $1.49M | $4.85M | $756.67K | $205 | – |
| FY2025 PEO2 | $0 | $0 | $756.67K | $205 | – |
| FY2024 James L. Cunniff | $3.00M | $4.40M | $552.90K | $140 | – |
| FY2024 PEO1 | $3.00M | $4.40M | $552.90K | $140 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of June 30, 2026, we had 197 employees, 195 of which were full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 3, 2011 | Delisting | Notice of delisting from exchange (Form 25) |
| Sep 29, 2011 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 22, 2011 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 13, 2010 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 30, 2010 | Listing | Registration of securities on an exchange (Form 8-A) |